박셀바이오
4,260KRWMarket close of 10/20 (Tue)
Up +1.67%+70KRWMarket close of 10/20 (Tue)
Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/21 (Wed)4,245KRWDown -0.35%
Preliminary · just after the close · replaced by official KRX data tomorrow morning
- Open
- 4,160
- High
- 4,325
- Low
- 4,150
- Day range
- Day range low 4,150 high 4,325, open 4,160, close 4,260, previous close 4,190
- Volume
- 8×10K shares
- 321.46 million KRW 0.92× the 20-session average
Market close of 10/20 (Tue)
Where it sits in the 1-year range
9%9% of the way up from the lowest close in 1 year (252 sessions) · -61.3% from the high
Usual range
Nothing unusual in the 3 checked items
Free · no sign-inSource from 2021-05-17
Points to check
- Earningsnot verifiedThe last four quarters are incomplete, so not verified
- Recent filingsnot verifiedOutside filing data coverage, so not verified
- Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified
The other 3 are within the usual range
- Daily move+1.67%usual range
- Trading value0.9×usual range
- Data date10/20 (Tue)Market close
See the full check report
Filings in the last 2 years · 1
Material events are checked for the top 400 stocks only — this stock shows periodic reports only.
- 2024-11-14Quarterly report (2024.09)
Same sector · 바이오 R&D
Down -2.19%· 16 of 64 stocks up, preferred shares excluded · trading value 190.5B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 알테오젠 | Close over the last 20 sessions -9.6% | Down -3.35% | 51.1B KRW |
| 올릭스 | Close over the last 20 sessions -12.2% | Down -4.03% | 19.1B KRW |
| 디앤디파마텍 | Close over the last 20 sessions -11.8% | Down -1.93% | 15.1B KRW |
| 리가켐바이오 | Close over the last 20 sessions -15.4% | Down -1.41% | 12.1B KRW |
| 프로티나 | Close over the last 20 sessions +31.8% | Up +7.38% | 10.0B KRW |
Schedule
- Next data 10/22 (Thu) after 08:50
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 81% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.